Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TheraGenetics has completed an agreement with the Centre for Addiction and Mental Health in Ontario, Canada, to license intellectual property related to methods and kits for determining the susceptibility of a patient to certain side-effects of anti-depressants.
Subscribe to our email newsletter
According to TheraGenetics, the strategic expansion into the area of depression underscores the company’s commitment to licensing new technologies to build a foundation for future diagnostic tests for the most common central nervous system conditions. Centre for Addiction and Mental Health (CAMH) is said to share TheraGenetics’s commitment to improving patient care and treatment.
Richard Kivel, CEO of TheraGenetics, said: “The intellectual property we licensed from CAMH further augments our capabilities to innovate pharmacogenetic diagnostics tests in a broad range of disorders, including schizophrenia, depression, bipolar disorder, Alzheimer’s disease and attention-deficit hyperactivity disorder.”